The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

A probiotic composition is provided. The probiotic composition comprises different probiotic strains. The probiotic composition generally comprises: Bifidobacterium lactis; Lactobacillus acidophilus; Lactobacillusplantarum; Lactobacillus rhamno-sus; and Lactobacillusparacasei. The composition comprising suchprobiotic strains has abeneficial effect onthe intestinal microbiome diversity, improves the Firmicutes/Bacteroidetes ratio, and encourages growth of beneficial microbiota not contained in the composition itself. Also provided herein are uses of the probiotic composition.

A probiotic composition is provided. The probiotic composition comprises different probiotic strains. The probiotic composition generally comprises: Bifidobacterium lactis; Lactobacillus acidophilus; Lactobacillusplantarum; Lactobacillus rhamno-sus; and Lactobacillusparacasei. The composition comprising suchprobiotic strains has abeneficial effect onthe intestinal microbiome diversity, improves the Firmicutes/Bacteroidetes ratio, and encourages growth of beneficial microbiota not contained in the composition itself. Also provided herein are uses of the probiotic composition.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

A nutritional composition obtainable by fermenting a mixture comprising protein, carbohydrate and fat, wherein the major source of protein is potato protein, and wherein the mixture is fermented by lactic acid-producing bacteria.

A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having β-glycosidase activity or a β-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both β-glycosidase activity and esterase activity or an enzyme having both β-glycosidase activity and esterase activity, (iv) a first probiotic having β-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having β-glycosidase activity and an esterase, (vi) a β-glycosidase and a probiotic having esterase activity and (vii) a β-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein. The composition can be for treating or preventing impaired mobility in an older adult; stimulating bone formation and/or inhibiting bone resorption; treating or preventing synovitis in an individual in need or at risk thereof or treating or preventing articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or preventing or treating cartilage breakdown.

The present invention relates to fermented plant-based compositions and methods of making the same.

An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

A probiotic egg wash for the exterior surface of the eggshell that is ingested by the developing embryo resulting in an established GI tract microbiome that promotes health and outcompetes potential pathogens such as Salmonella is provided herein. In the preferred embodiment, the probiotic wash is composed at least of L. casei, L. rhamnosus, L. planitarum, L. paracasei, and/or B. lactis at a concentration of between 10.sup.2 to 10.sup.9 CFU per egg.